Annual Review I 2022 Wonderful Moments of Rocky Biology-Novamab

Our Story

Share the latest information

Home News Company News

Annual Review I 2022 Wonderful Moments of Rocky Biology

2022-12-30

314

Previous：

Progress of new drugs I The clinical trial of Novamab's inhaled TSLP nanoantibody drug LQ043H was approved by CDE

Next：

New drug progress I LQ036, the world's first inhaled nano-antibody drug for the treatment of moderate and severe asthma, has completed the administration of the first patient in China's clinical phase I!

Related recommendations

Good news! Novamab Ranks in the Top 10 Most Promising Biopharma Companies on the Huayi List 2024

Novamab, the world's first inhaled nanobodycompany, officially announced the completion of nearly 300 million RMB in Series B financing

International Conference 及2024 BIO International Convention

Novamab: LQ036 Completes The First Patient Dosing in Phase IIa Clinical Study
— The First Inhaled Biological Agent in China Provides A New Treatment Option for Asthma Patients